AUS
NZ
UK
CA
USA
IND
Highlights
- Record Monthly Sales: PolyNovo reported $10.1M in unaudited sales for November 2024, marking the company's highest monthly performance to date.
- Geographic Expansion:
- United States: November sales reached $7.0M, contributing to year-to-date (YTD) sales of $33.9M, reflecting a 27.3% increase compared to last year.
- Rest of World: Sales of $3.1M for November, with YTD sales of $10.5M, up 24.0% year-on-year.
- PolyNovo has achieved market leadership in the UK and Germany for full-thickness burns and is now expanding into soft-tissue reconstruction, disrupting traditional oncological excision and dermatology practices.
- Total Group Revenue: Including contributions from BARDA, PolyNovo recorded $11.0M in total group revenue for November, with YTD revenue of $49.6M, reflecting a 25.4% increase year-on-year.
PolyNovo (ASX:PNV) has reached a major milestone, with unaudited sales of $10.1M in November 2024, marking the company’s highest-ever monthly sales performance. This growth reflects continued demand for PolyNovo's NovoSorb® product line, particularly in key global markets. The company’s strong performance in the United States, alongside its expanding presence in international markets, demonstrates the widespread adoption of its advanced wound care solutions.
Geographic Expansion and Market Leadership
In the United States, PolyNovo achieved $7.0M in monthly sales, contributing to year-to-date sales of $33.9M, a significant 27.3% increase compared to the previous year. The company’s Rest of World sales also performed well, reaching $3.1M for the month and $10.5M year-to-date, marking a 24.0% increase year-on-year.
PolyNovo has secured market leadership in the UK and Germany for full-thickness burns and is now making strides in soft-tissue reconstruction. This marks a shift in the medical field as PolyNovo’s technology challenges traditional oncological excision and surgical dermatology practices. By addressing unmet needs in these areas, the company is poised for continued growth and market expansion.
Total Group Revenue and Future Outlook
PolyNovo’s total group revenue for November 2024 reached $11.0M, including contributions from BARDA (Biomedical Advanced Research and Development Authority). Year-to-date revenue of $49.6M represents a 25.4% increase compared to the same period last year, further illustrating the company’s strong financial performance.
Looking ahead, PolyNovo remains committed to advancing its NovoSorb® technology and expanding its product portfolio. The company is exploring new opportunities in breast sling, hernia, and orthopedic applications, alongside its current focus on dermal regeneration. With a robust pipeline and growing market presence, PolyNovo is well-positioned for continued success in 2025 and beyond.
Market Impact
Following the announcement of its record sales, PolyNovo’s share price surged 4.87%, reaching $2.05 per share. This increase reflects strong investor confidence in the company’s innovative products and promising growth trajectory, positioning PolyNovo as a leader in advanced wound care solutions.
